Acute myeloid leukemia, often called AML, is one of the most aggressive and difficult blood cancers to treat. Every year thousands of people are diagnosed with it, and many patients relapse even after strong chemotherapy.
Doctors have long known that AML can come back because a small group of cells survives treatment and later rebuilds the cancer. Now, new research has uncovered an important weakness inside these stubborn cells, offering hope for more effective treatments in the future.
The study was co-led by scientists at the Indiana University School of Medicine and published in the journal Leukemia. The researchers focused on leukemia stem cells, which are considered the root of AML.
These cells behave like seeds. Even if chemotherapy destroys most cancer cells, leukemia stem cells can hide, survive, and regrow the disease months or years later. Because of this, AML has a high relapse rate and a poor long‑term survival outcome.
According to national cancer statistics, the five‑year survival rate for AML is only about 33 percent. Around 22,000 new cases were reported in 2025 in the United States alone.
Many patients respond to treatment at first, but the disease often returns in a more resistant form. Scientists have been trying to understand what makes leukemia stem cells so strong and how to stop them from surviving therapy.
In this new study, researchers examined leukemia stem cells taken from AML patients both at the time of diagnosis and after the cancer came back.
They discovered that these cells rely heavily on a biological pathway linked to inflammation. Inflammation is normally the body’s natural response to injury or infection. However, cancer cells can sometimes hijack these signals to help themselves survive.
The pathway highlighted in this research is called interleukin‑1, or IL‑1, signaling. IL‑1 is a molecule used by the immune system to send danger signals and trigger inflammation.
The scientists found that IL‑1 activity was unusually high in leukemia stem cells at both the beginning of the disease and after relapse. This suggested that AML cells may depend on IL‑1 as a survival tool.
To test this idea, the team used genetic methods to reduce IL‑1 signaling in AML cells grown in the lab. When the signal was weakened, the leukemia cells lost much of their ability to grow and form colonies. They also struggled to restart leukemia, showing that IL‑1 is important for keeping these dangerous cells alive.
After identifying this weakness, the researchers designed a new experimental drug called UR241‑2. This compound blocks two key proteins, IRAK1 and IRAK4, that help transmit IL‑1 signals inside cells. By shutting down these proteins, UR241‑2 interrupts the inflammation pathway that leukemia stem cells rely on.
The drug was tested in animal models. In mice with AML, UR241‑2 significantly reduced leukemia levels. Importantly, it did not seriously harm normal blood‑forming cells, which is a common problem with many cancer drugs.
This selectivity is critical because safer treatments are urgently needed for AML patients, who often suffer strong side effects from chemotherapy.
The findings suggest that targeting IL‑1 signaling could work alongside standard treatments to eliminate leukemia stem cells and reduce the chance of relapse. Similar drugs aimed at IRAK proteins are already being studied for other cancers and immune diseases, which increases the likelihood that this strategy could eventually move into human clinical trials.
While UR241‑2 is still in early development and not yet available for patients, the discovery marks an important step forward. It provides clear evidence that AML cells are not unstoppable—they have hidden weaknesses that scientists can attack.
Overall, this study shows strong promise. The research carefully examined patient cells, tested the theory in the lab, and confirmed the results in animal models.
However, human trials are still needed to prove safety and effectiveness in real patients. If future studies succeed, this approach could become part of a combination therapy to improve survival and reduce recurrence in AML.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more health information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Copyright © 2025 Knowridge Science Report. All rights reserved.
